[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-359003-105":59,"doc-detail-359003-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","the-features-and-prognostic-value-of-arid1a-mutation-and-protein-expression-in-endometrial-cancer-of-no-specific-molecular-profile-nsmp-subtype-a-retrospective-study-in-a-large-chinese-cohort","The features and prognostic value of ARID1A mutation and protein expression in endometrial cancer of no specific molecular profile (NSMP) subtype - a retrospective study in a large Chinese cohort","","Purpose Endometrial cancer (EC) of no specific molecular profile (NSMP) subtype represents the majority of EC cases and shows substantial heterogeneity. This retrospective study investigates how ARID1A mutation and ARID1A protein expression relate to clinicopathologic features and progression-free survival (PFS) in a large Chinese cohort. Methods NSMP patients undergoing primary surgery and next-generation sequencing were evaluated for ARID1A alterations, protein expression, and PFS. Results Among 151 analyzed patients, ARID1A mutations occurred in 49.0%, including mostly loss-of-function variants, and were linked to poorer PFS. Conclusion ARID1A mutation and protein expression may serve as biomarkers to refine NSMP classification and inform more precise therapeutic targeting.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-features-and-prognostic-value-of-arid1a-mutation-and-protein-expression-in-endometrial-cancer-of-no-specific-molecular-profile-nsmp-subtype-a-retrospective-study-in-a-large-chinese-cohort/359003/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-features-and-prognostic-value-of-arid1a-mutation-and-protein-expression-in-endometrial-cancer-of-no-specific-molecular-profile-nsmp-subtype-a-retrospective-study-in-a-large-chinese-cohort/359003.png","ImageObject",300,407,{"name":92,"@type":93},"Genevieve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-15","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the main purpose of the study in NSMP endometrial cancer?","Question",{"text":113,"@type":114},"To explore the role of ARID1A mutation and ARID1A protein expression in NSMP EC patients, and assess their relationship with progression-free survival (PFS).","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were ARID1A mutations and protein expression evaluated?",{"text":118,"@type":114},"ARID1A mutation status was determined using next-generation sequencing, and ARID1A protein expression was assessed by immunohistochemistry (IHC).",{"name":120,"@type":111,"acceptedAnswer":121},"What did the study conclude about ARID1A as a biomarker for NSMP?",{"text":122,"@type":114},"ARID1A mutation was associated with worse PFS, and ARID1A protein expression correlated with ARID1A mutation; together with ER/PR and PIK3CA status, they may help subclassify NSMP and guide more precise therapeutic targeting.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},359003,1790196494,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Journal of Cancer Research and Clinical Oncology (2026) 152:66  \n[https://doi.org/10.1007/s00432-026-06440-w](https://doi.org/10.1007/s00432-026-06440-w)  \nRESEARCH  \nThe features and prognostic value of ARID1A mutation and protein expression in endometrial cancer of no specific molecular profile (NSMP) subtype: a retrospective study in a large Chinese cohort  \nXinhui Yuan1,2 · Mengyuan Cai2,3,4 · Changmin Yu1,2 · Zhengyao Zhai1,2 · Xiaoyan Zhou2,3,4 · Huaying Wang1,2 · Yulan Ren1,2  \nReceived: 12 January 2026 / Accepted: 12 February 2026 © The Author(s) 2026  \nAbstract  \nPurpose Endometrial cancer (EC) of no specific molecular profile (NSMP) subtype constitutes the majority of EC and shows significant heterogeneity. This study aims to explore the role ofARID1A mutation and protein expression in NSMP EC patients in a large Chinese cohort.  \nMethods A retrospective analysis was conducted on patients with NSMP EC who underwent primary surgery and next-generation sequencing (NGS) . Clinicopathologic features, ARID1A mutation, protein expression and progression-free survival (PFS) were analysed in our study.  \nResults A total of 547 patients were enrolled in the study, and 151 patients with NSMP were included in the final analyses. ARID1A mutations were identified in 49.0%(74/151) patients, in which 85.1%(63/74) of them were loss-of-function mutations and 27.0%(20/74) with multiple mutations. Compared to patients with ARID1A wild-type, those with ARID1A mutations were older (p= 0.032) and had higher staging (p= 0.022), and ARID1A mutation was associated with poorer PFS (p = 0.019). Among 90 patients with immunohistochemistry (IHC), the absence of ARID1A protein expression was significantly associated with ARID1A mutation (p\u003C 0.001), especially with ARID1A multiple mutations (p= 0.042) . The aberrant PI3K pathway was more likely to occur in patients with ARID1A mutations (p = 0.006). ER/PR negative expression, PIK3CA hotspot mutations, with ARID1A mutations were correlated with poor PFS (p\u003C 0.001; p= 0.013) .  \nConclusion ARID1A mutation was associated with worse PFS for patients with NSMP. ARID1A protein expression was significantly associated with ARID1A mutation. ARID1A mutation, with ER/PR expression and PIK3CA mutation status, could serve as the potential biomarkers to subclassify NSMP subtype and provide more precise therapeutic target.  \nKeywords Endometrial cancer (EC) · No specific molecular profile (NSMP) · ARID1A · Prognosis  \nXinhui Yuan and Mengyuan Cai contributed equally as the first authors.  \n􀀍 Yulan Ren [yulan_ren@shca.org.cn](yulan_ren@shca.org.cn)  \n1 Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China  \n2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China  \n3 Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China  \n4 Institute of Pathology, Fudan University, Shanghai 200032, China  \nIntroduction  \nEndometrial cancer (EC) is one of the most common gynecologic cancers for women with an increasing incidence and mortality worldwide. In China, there were an estimated 77,700 new cases and 13,500 deaths in 2022 (Han et al. 2024) . The molecular classification of EC, including polymerase-epsilon mutated (POLEmut), microsatellite instability-high (MSI-H)/mismatch repair deficient (MMRd), no specific molecular profile (NSMP) and p53 abnormal (p53abn), was widely applied in clinical practice nowadays and incorporated into the International Federation of Gynecology and Obstetrics (FIGO) staging in 2023 (The Cancer Genome Atlas Research Network and Levine 2013; Berek  \n1 3  \net al. 2023) . More accurate postoperative therapies could be provided for EC patients based on this molecular classification, while it remains insufficient for NSMP EC patients, who account for approximately 50% of all primary ECs, but with significant heterogeneity (The Cancer Genome Atlas Research Network and Levine 2013; Depreeuw","cbCaifuxT5XJgyjp","https://ap.wps.com/l/cbCaifuxT5XJgyjp","pdf",2221814,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Introduction\n# Methods\n## Study design and patient population","[{\"question\":\"What was the main purpose of the study in NSMP endometrial cancer?\",\"answer\":\"To explore the role of ARID1A mutation and ARID1A protein expression in NSMP EC patients, and assess their relationship with progression-free survival (PFS).\"},{\"question\":\"How were ARID1A mutations and protein expression evaluated?\",\"answer\":\"ARID1A mutation status was determined using next-generation sequencing, and ARID1A protein expression was assessed by immunohistochemistry (IHC).\"},{\"question\":\"What did the study conclude about ARID1A as a biomarker for NSMP?\",\"answer\":\"ARID1A mutation was associated with worse PFS, and ARID1A protein expression correlated with ARID1A mutation; together with ER/PR and PIK3CA status, they may help subclassify NSMP and guide more precise therapeutic targeting.\"}]","The features and prognostic value of ARID1A mutation and protein expression in endometrial cancer of no specific molecular profile (NSMP) subtype - a retrospective study in a large Chinese cohort | PDF",1790135845,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/22cb19a62b786b402b81c4b8df2887ce.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1814893b6e577f3a737f509998d0dfc8.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0dbde58dda9a4be55dfb5b09fdaa197b.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1d9dad4603bc74c1f91a3c49f22c5f2f.webp",980,1301]